Znanstveni rad - Izvorni znanstveni rad
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma
Annals of Hematology, 95 (2016), 7; 1129-1136. https://doi.org/10.1007/s00277-016-2676-0

Aurer, Igor; Nemet, Damir; Mitrović, Zdravko; Dujmović, Dino; Bašić-Kinda, Sandra; Radman, Ivo; Sertić, Dubravka; Šantek, Fedor; Kralik, Marko; Dotlić, Snježana; Mazić, Sanja; Labar, Boris

Citirajte ovaj rad

Aurer, I., Nemet, D., Mitrović, Z., Dujmović, D., Bašić Kinda, S., Radman, I. ... Labar, B. (2016). High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. Annals of Hematology, 95. (7), 1129-1136. doi: 10.1007/s00277-016-2676-0

Aurer, Igor, et al. "High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma." Annals of Hematology, vol. 95, br. 7, 2016, str. 1129-1136. https://doi.org/10.1007/s00277-016-2676-0

Aurer, Igor, Damir Nemet, Zdravko Mitrović, Dino Dujmović, Sandra Bašić Kinda, Ivo Radman, Dubravka Sertić, et al. "High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma." Annals of Hematology 95, br. 7 (2016): 1129-1136. https://doi.org/10.1007/s00277-016-2676-0

Aurer, I., et al. (2016) 'High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma', Annals of Hematology, 95(7), str. 1129-1136. doi: 10.1007/s00277-016-2676-0

Aurer I, Nemet D, Mitrović Z, Dujmović D, Bašić Kinda S, Radman I, i sur.. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. Annals of Hematology [Internet]. 06.2016. [pristupljeno 25.05.2024.];95(7):1129-1136. doi: 10.1007/s00277-016-2676-0

I. Aurer, et al., "High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma", Annals of Hematology, vol. 95, br. 7, str. 1129-1136, Lipanj 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:978993. [Citirano: 25.05.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.